United States · Health Care · USD (Thousands) · Annual
Reported figures and Equlion model projections for the next 5 years.
Amounts in USD (thousands); stock price per share. Values that are missing or fail Equlion's automated data-quality checks are shown as “-”. Projections are model estimates, not investment advice.
Want the full financial forecast report for SANGAMO THERAPEUTICS, INC? It covers the balance sheet, income statement, cash flow and Equlion model projections.
| Key metrics | Actual | Forecast | ||||
|---|---|---|---|---|---|---|
| Metric | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 |
| ROE | -185.39% | -4.74% | 7.18% | -1.35% | -3.5% | -2.32% |
|---|---|---|---|---|---|---|
| ROA | -73.38% | -1.01% | 1.48% | -0.27% | -0.66% | -0.4% |
| Gross Margin | 100% | 88.5% | 88.27% | 88.13% | 87.83% | 87.87% |
| Net Margin | -169.45% | -1.59% | 2.25% | -0.39% | -0.92% | -0.55% |
| Total Assets | $101,635.00K | $106,422.88K | $111,594.84K | $117,181.72K | $123,216.82K | $129,729.61K |
| Net Income | -$97,941.00K | -$1,053.70K | $1,616.80K | -$311.79K | -$791.74K | -$510.08K |